KRMD

Company Overview — What Does KORU Medical Systems, Inc. Do?

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. KORU Medical Systems, Inc. (KRMD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Linda M. Tharby and employs approximately 80 people. With a market capitalization of $198M, KRMD is one of the notable companies in the Healthcare sector.

KORU Medical Systems, Inc. (KRMD) Stock Rating — Reduce (April 2026)

As of April 2026, KORU Medical Systems, Inc. receives a Reduce rating with a composite score of 38.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.KRMD ranks #3,190 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, KORU Medical Systems, Inc. ranks #479 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KRMD Stock Price and 52-Week Range

KORU Medical Systems, Inc. (KRMD) currently trades at $4.21. The stock lost $0.16 (3.7%) in the most recent trading session. The 52-week high for KRMD is $6.61, which means the stock is currently trading -36.3% from its annual peak. The 52-week low is $1.86, putting the stock 126.3% above its annual trough. Recent trading volume was 123K shares, suggesting relatively thin trading activity.

Is KRMD Overvalued or Undervalued? — Valuation Analysis

KORU Medical Systems, Inc. (KRMD) carries a value factor score of 33/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 11.53x, versus the sector average of 2.75x. The price-to-sales ratio is 5.12x, compared to 1.66x for the average Healthcare stock.

At current multiples, KORU Medical Systems, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

KORU Medical Systems, Inc. Profitability — ROE, Margins, and Quality Score

KORU Medical Systems, Inc. (KRMD) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -21.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -13.2% versus the sector average of -33.1%.

On a margin basis, KORU Medical Systems, Inc. reports gross margins of 62.5%, compared to 71.5% for the sector. The operating margin is -11.3% (sector: -66.1%). Net profit margin stands at -10.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 23.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KRMD Debt, Balance Sheet, and Financial Health

KORU Medical Systems, Inc. has a debt-to-equity ratio of 65.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.44x, indicating strong short-term liquidity. Total debt on the balance sheet is $451,210. Cash and equivalents stand at $8M.

KRMD has a beta of 1.08, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for KORU Medical Systems, Inc. is 48/100, reflecting average volatility within the normal range for its sector.

KORU Medical Systems, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, KORU Medical Systems, Inc. reported revenue of $38M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-4M. Gross margin was 62.5%. Operating income came in at $-4M.

In FY 2025, KORU Medical Systems, Inc. reported revenue of $41M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-3M. Gross margin was 62.3%. Revenue grew 22.2% year-over-year compared to FY 2024. Operating income came in at $-3M.

In Q3 2025, KORU Medical Systems, Inc. reported revenue of $10M. Net income for the quarter was $-777,966. Gross margin was 60.2%. Revenue grew 27.2% year-over-year compared to Q3 2024. Operating income came in at $-867,679.

In Q2 2025, KORU Medical Systems, Inc. reported revenue of $10M. Net income for the quarter was $-206,867. Gross margin was 63.5%. Revenue grew 20.9% year-over-year compared to Q2 2024. Operating income came in at $-312,655.

Over the past 8 quarters, KORU Medical Systems, Inc. has demonstrated a growth trajectory, with revenue expanding from $8M to $38M. Investors analyzing KRMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KRMD Dividend Yield and Income Analysis

KORU Medical Systems, Inc. (KRMD) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KRMD Momentum and Technical Analysis Profile

KORU Medical Systems, Inc. (KRMD) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 14/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

KRMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, KORU Medical Systems, Inc. (KRMD) ranks #479 out of 838 stocks based on the Blank Capital composite score. This places KRMD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KRMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KRMD vs S&P 500 (SPY) comparison to assess how KORU Medical Systems, Inc. stacks up against the broader market across all factor dimensions.

KRMD Next Earnings Date

No upcoming earnings date has been announced for KORU Medical Systems, Inc. (KRMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KRMD? — Investment Thesis Summary

The quantitative profile for KORU Medical Systems, Inc. suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 33/100 indicates premium valuation.

In summary, KORU Medical Systems, Inc. (KRMD) earns a Reduce rating with a composite score of 38.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KRMD stock.

Related Resources for KRMD Investors

Explore more research and tools: KRMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KRMD head-to-head with peers: KRMD vs AZN, KRMD vs SLGL, KRMD vs VMD.